Your browser doesn't support javascript.
Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.
Brothers, Sarah; Palayew, Adam; Simon, Caty; Coulter, Abby; Strichartz, Knina; Voyles, Nick; Vincent, Louise.
  • Brothers S; Department of Sociology, Pennsylvania State University, University Park, USA. sarah.brothers@psu.edu.
  • Palayew A; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Simon C; Methadone Advocacy Working Group, National Survivors Union, Greensboro, NC, USA.
  • Coulter A; NC Survivors Union, Greensboro, NC, USA.
  • Strichartz K; Whose Corner Is It Anyway, Holyoke, MA, USA.
  • Voyles N; Methadone Advocacy Working Group, National Survivors Union, Greensboro, NC, USA.
  • Vincent L; Methadone Advocacy Working Group, National Survivors Union, Greensboro, NC, USA.
Harm Reduct J ; 20(1): 31, 2023 03 09.
Article in English | MEDLINE | ID: covidwho-2253084
ABSTRACT

BACKGROUND:

During COVID-19, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed Methadone Maintenance Treatment (MMT) programs to relax in-person MMT requirements to reduce COVID-19 exposure. This study examines patient-reported changes to in-person methadone clinic attendance requirements during COVID-19.

METHODS:

From June 7, 2020, to July 15, 2020, a convenience sample of methadone patients (N = 392) were recruited in collaboration with National Survivors Union (NSU) in 43 states and Washington D.C. through social media (Facebook, Reddit, Twitter, and Web site pop-ups). The community-driven research (CDR) online survey collected information on how patient take-home methadone dosing and in-person drug testing, counseling, and clinic visit frequency changed prior to COVID-19 (before March 2020) to during COVID-19 (June and July 2020).

RESULTS:

During the study time period, the percentage of respondents receiving at least 14 days of take-home doses increased from 22 to 53%, while the percentage receiving one or no take-home doses decreased from 22.4% before COVID-19 to 10.2% during COVID-19. In-person counseling attendance decreased from 82.9% to 19.4%. While only 3.3% of respondents accessed counseling through telehealth before COVID-19, this percentage increased to 61.7% during COVID-19. Many respondents (41.3%) reported visiting their clinics in person once a week or more during COVID-19.

CONCLUSIONS:

During the first wave of COVID-19, methadone patients report decreased in-person clinic attendance and increased take-home doses and use of telehealth for counseling services. However, respondents reported considerable variations, and many were still required to make frequent in-person clinic visits, which put patients at risk of COVID-19 exposure. Relaxations of MMT in-person requirements during COVID-19 should be consistently implemented and made permanent, and patient experiences of these changes should be explored further.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Opioid-Related Disorders Type of study: Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: Harm Reduct J Year: 2023 Document Type: Article Affiliation country: S12954-023-00756-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Opioid-Related Disorders Type of study: Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: Harm Reduct J Year: 2023 Document Type: Article Affiliation country: S12954-023-00756-3